|4.||Uterine Hemorrhage (Uterine Bleeding)
|5.||Leiomyoma (Uterine Fibroids)
|1.||Wang, Peng-Hui: 13 articles (12/2012 - 03/2003)|
|2.||Kumakiri, Jun: 12 articles (01/2014 - 05/2005)|
|3.||Kitade, Mari: 10 articles (01/2014 - 05/2005)|
|4.||Kikuchi, Iwaho: 10 articles (01/2014 - 05/2005)|
|5.||Liu, Wei-Min: 8 articles (12/2012 - 02/2002)|
|6.||Tinelli, Andrea: 7 articles (01/2015 - 10/2009)|
|7.||Malvasi, Antonio: 7 articles (01/2015 - 10/2009)|
|8.||Takeda, Satoru: 7 articles (01/2014 - 05/2008)|
|9.||Ishiko, Osamu: 7 articles (08/2012 - 02/2002)|
|10.||Salo, Tuula: 6 articles (09/2015 - 09/2009)|
|1.||Gonadotropin-Releasing Hormone (GnRH)FDA Link
07/01/1995 - "Gonadotropin-releasing hormone agonist-treated patients had a significant reduction in uterine and myoma volume when compared with the placebo group (P < .01). "
06/01/2009 - "More than 80% of women in this study benefited from the use of GnRH agonist to produce menopause, suggesting that this can be an alternative choice for managing perimenopausal women with symptomatic uterine myomas."
09/01/2010 - "GnRH analogue treatment before hysteroscopic resection of G0-G1 10-35 mm submucous myomas was effective in reducing operative times, fluid absorption, and difficulty of the procedure."
08/15/1985 - "Luteinizing hormone-releasing hormone agonist is the first medication demonstrated effective in reducing the size of uterine myomas."
02/01/1992 - "Clinical trials with gonadotropin-releasing hormone agonists consistently have demonstrated efficacy for decreasing both myoma size and uterine volume. "
|2.||Levonorgestrel (Plan B)FDA LinkGeneric
11/01/2008 - "Levonorgestrel-releasing intrauterine system use in uterine myomas. "
11/01/2008 - "The effect of levonorgestrel intrauterine system on uterine myomas: a 1-year follow-up study."
10/01/2006 - "The use of levonorgestrel - IUD in the treatment of uterine myoma in Thai women."
01/01/2005 - "To determine the efficacy of levonorgestrel-releasing intrauterine device (LNG-IUD) insertion in menorrhagic patients who have at least one type II myoma according to the European Society of Hysteroscopy. "
10/01/2006 - "This study was designed to evaluate the potential usefulness of the levonorgestrel-releasing intrauterine device (LNG - IUD ; Mirena) in treating women with uterine myomas. "
|3.||Estrogens (Estrogen)FDA Link
12/01/2013 - "The aim of the present study is to evaluate the long term effects of estrogen-progestogen therapy (EPT) on uterine myomas volume in postmenopausal women. "
01/01/2014 - "Expression of estrogen receptor β was not affected by age of the woman or size of myoma. "
12/01/2013 - "Myoma volume changes were not significantly different in the subgroups according to the route of estrogen administrations and the method of progestogen administrations. "
01/01/2012 - "The mechanism of tumorigenesis is unknown, but evidence suggests that estrogens regulate cell proliferation and myoma growth. "
01/01/2005 - "Using EPR, it was shown that uterine myoma was characterized by an estrogen-dependent intensification of the processes of free-radical oxidation, which correlated with a degree of hormonal changes. "
01/01/2002 - "Triptoreline is a GnRHa which has been found to be effective in reducing myoma volume, but this effect could not be deactivated with tibolone. "
01/01/2000 - "Tibolone seems a valid alternative in menopausal patients with uterine myomas as it provides adequate relief from menopausal symptoms and avoids volume increase of the uterus and myomas."
10/31/2001 - "The aim of the present study is to evaluate the long term effects of Tibolone (Livial) on uterine myomas volume as well as on uterine arteries pulsatility index (PI) in postmenopausal women. "
01/01/2014 - "The median myoma volume decreased upon iCR by as much as -30% (P = 0.016) but increased upon tibolone by +4.7%. "
07/25/2002 - "There are no statistical significant differences between tibolone and transdermal hormonal replacement therapy regimens in respect to increase in the size of myoma uteri."
|5.||Mifepristone (RU 486)FDA Link
01/01/2014 - "As a result, mifepristone single-treated group represents the most significant reduction in myoma cell viability and proliferation. "
11/01/2008 - "To estimate the efficacy of daily administration of 5 mg compared with 10 mg of mifepristone for the treatment of uterine myomas. "
05/01/2005 - "Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas."
06/01/2013 - "This study was undertaken to evaluate efficacy and safety of low dose mifepristone in medical management of myoma and to compare two doses - 10 vs. 25 mg/day. "
01/01/2013 - "Treatment of Uterine Myoma with 2.5 or 5 mg Mifepristone Daily during 3 Months with 9 Months Posttreatment Followup: Randomized Clinical Trial."
|6.||Goserelin (Zoladex)FDA Link
01/01/1999 - "The significant reduction in myoma volume in 6 patients due to presurgical treatment with Zoladex made smaller operation--myomectomy, possible. "
07/01/2001 - "The obtained results point to efficacy of Zoladex in decreasing the volumes of both myomas and uterus by more than 50%, which correlates with literature data. "
07/01/2001 - "This study investigated the efficacy of Zoladex depot 3.6 mg (goserelin acetate) during a 4-month treatment of infertile patients with uterine myomas of different size and location. "
07/01/2001 - "Clinical efficacy of goserelin (Zoladex) in the treatment of uterine myomas in infertile patients."
01/01/1996 - "Zoladex Myoma Study Group."
04/01/2008 - "Vasopressin (12 IU) injection around the myoma is a simple, effective, and safe homeostatic procedure during LM. "
11/01/2014 - "To evaluate the efficacy of transcervical intralesional vasopressin injection to submucous myoma in hysteroscopic myomectomy from 2011 to 2014. "
11/01/2014 - "Injecting a dilute vasopressin solution directly into a vascular submucosal myoma during hysteroscopic resection can assist with hemostasis and visualization, enabling complete resection."
11/01/2014 - "Forty premenopausal women with symptomatic submucous myoma requiring hysteroscopic myomectomy were randomized to transcervical intralesional vasopressin injection or placebo in a 4:4 ratio. "
01/01/2014 - "No significant between-group difference was observed in age (p = .975), body mass index (p = .778), GnRHa administration (p = .059), intraoperative vasopressin dose (p = .364), intraoperative blood loss (73.8 ± 64.1 vs. 59.3 ± 54.0 mL, respectively; p = .199), myoma mass (212.6 ± 133.3 vs. 208.3 ± 198.4 g, respectively; p = .134), ΔHb (p = .517), or postoperative hospital stay (p = .314). "
|8.||Leuprolide (Lupron)FDA LinkGeneric
09/01/2015 - "Comparison of Laparoscopic Myomectomy in Large Myomas With and Without Leuprolide Acetate."
09/01/2011 - "To compare these data in a case-control study, we analyzed a matched control group of 12 patients treated with leuprolide acetate (1.88 mg monthly) for 6 months having uterine myoma. "
04/01/1997 - "Leuprolide-treated myomas."
09/01/1995 - "Leuprolide acetate treatment and myoma arterial size."
02/01/1995 - "Myoma size and location were assessed by endovaginal ultrasound before preoperative treatment with depot leuprolide. "
12/01/2011 - "Progestins, although used widely, remain poorly effective as they promote myoma cell growth. "
09/11/1993 - "Resection of submucosal myoma usually enables treatment with progestins to be discontinued. "
10/01/2007 - "Long-term use of progestogens--effects on endometriosis, adenomyosis and myomas."
10/01/1970 - " In addition to the classical indications for oral progestins (menstrual irregularities during the menopause, hypermenorrhea, corpus luteum insufficiency, myoma), retroprogesterones may be used for menstrual irregularities in adolescence, for the maintenance of threatened pregnancy, and possibly as an ovulation stimulant."
10/01/2007 - "Effective new therapies for endometriosis have been introduced during the last 30 years and progestins now have a place in the symptomatic management of pain, bleeding and other symptoms caused by endometriosis, adenomyosis or myoma, particularly when long-term medication is indicated or when repeated courses of treatment are acceptable."
06/01/2002 - "The prolonged use of the last generation of oral contraceptives does not affect the uterine myomas volume increase and furthermore it produces a significant reduction in the duration of menstrual flow with a significant increase in hematocrit."
06/01/2002 - "The use of the last generation oral contraceptives for 2 years didn't increase significantly uterine myomas size; besides after 24 months there was a significant reduction of more than two days of menstrual flow, and a significant increase of two and a half points of hematocrit. "
06/01/2002 - " non-randomized perspective study on the effects of the last generation of oral contraceptives on uterine myomas during 24 months follow-up. "
01/01/2000 - "They were examined for RF of IHD and AS as well as some conditions of the reproductive system induced by oral contraceptives, replacement hormonal therapy, postmorbid period of OPH-gestosis, uterine myoma, ovarian failure. "
02/01/1998 - "We report a case of a patient with prolonged exposure to oral contraceptives, operated because of hypermenorrhea and 'myoma in statu nascendi'. "
|1.||Uterine Artery Embolization
08/01/2004 - "Uterine artery embolization is associated with a significant reduction in myoma and uterine volume. "
08/01/2003 - "Selective uterine artery embolization is effective for uterine myoma. "
12/01/2014 - "Combining myomectomy with uterine artery embolization is a safe and effective procedure in treating symptoms and reducing myoma and uterine volumes."
06/01/2013 - "Is uterine artery embolization for patients with large myomas safe and effective? "
03/01/2010 - "On the basis of consistent published scientific evidence, the American College of Obstetricians and Gynecologists has given uterine artery embolization (UAE) a level A recommendation as a viable alternative treatment for uterine myomas, describing it as a safe and effective option for appropriately selected women who wish to retain their uteri. "
07/01/2013 - "Hysterectomy is the most effective treatment for symptomatic myoma with no possible recurrence. "
03/01/2011 - "Myolysis is one of the procedures that is claimed to provide significant improvement in myoma status without hysterectomy. "
10/01/2008 - "Numerous procedures have been developed in recent decades that claim to provide significant improvement in myoma status without hysterectomy. "
11/01/2007 - "The proposed transfusion-infusion programs in abdominal hysterectomy for large-sized myomas by applying blood-preserving methods are effective in avoiding the use of donor blood components and accordingly in reducing the frequency of complications associated with transfusions of donor blood components, and improving the postoperative period."
09/01/2014 - "The study group comprised 456 women with myomas who met the inclusion criteria, and of these, 82 (17.98%) later underwent hysterectomy. "
|3.||Endometrial Ablation Techniques
05/01/2005 - "Complete removal of the myoma led to better results (p = .039), which were further improved by endometrial ablation (p = .022). "
10/01/1999 - "This study compares results of endometrial ablation alone and in combination with myoma coagulation. "
12/01/2011 - "Finally, economical outcomes of endometrial ablation in myomas haven't been assessed yet."
08/01/2009 - "Two-dimensional plots showing shrinkage of submucosal myomas versus the RODNeV indicated that shrinkage at six months after microwave endometrial ablation depends on the RODNeV. "
08/01/2009 - "To explore parameters relating to shrinkage of submucosal myomas after microwave endometrial ablation. "
01/01/2009 - "In the present retrospective study, we report our experience with a group of patients who consecutively underwent ultra-minilaparotomy myomectomy for single or multiple large myomas, with diameter greater than 5 cm, with emphasis on the safety and efficacy of this procedure. "
02/01/2007 - "To evaluate the therapeutic efficacy of laparoscopic uterine artery occlusion combined with myomectomy through a minilaparotomy in the treatment of recurrent uterine myomas, compared with myomectomy alone. "
01/01/2009 - "The results of this study suggest that ultra-minilaparotomy myomectomy with or without laparoscopic assistance might represent a safe and effective minimally invasive alternative to standard open myomectomy in the treatment of large myomas."
02/01/2007 - "Efficacy of combined laparoscopic uterine artery occlusion and myomectomy via minilaparotomy in the treatment of recurrent uterine myomas."
01/01/2013 - "The study included women with subserosal and/or intramural uterine myomas with a maximum diameter of ten cm. All patients underwent myomectomy by mini laparotomy. "
07/01/2009 - "Myoma therapy by uterine artery occlusion using laparoscopic ligation (UAOL) has been performed for many years and has proven effective, but limited information is available on its therapeutic mechanism. "
08/01/2009 - "This study demonstrated the superiority of laparoscopic uterine artery ligation combined with myomectomy in treatment of symptomatic myomas."
04/01/2013 - "Endoloop ligation is feasible for eliminating prolapsed pedunculated submucous myoma. "
04/01/2013 - "Endoloop ligation technique for prolapsed pedunculated submucous uterine myoma: utility and reliability."
11/01/2012 - "Comparison of laparoscopic myomectomy using in situ morcellation with and without uterine artery ligation for treatment of symptomatic myomas."